Search

everythinglearnresearchcommunity

for

Search:↓

Hair loss may be linked to the TRPS1 gene and protein, not just DHT. Amplifica's AMP-303 targets mesenchymal stem cells and shows promise in treating hair loss, unlike Pelage's PP405.

The user has been using 1mg finasteride every other day, 5% minoxidil daily, and microneedling every two weeks for three months to treat hair loss. They are happy with the progress and considering adding ketoconazole shampoo to their routine.

A 33-year-old male is documenting his hair regrowth progress using minoxidil, red light therapy, copper peptides, and micro-needling, with noticeable improvement in hair thickness and coverage. He plans to add a topical finasteride/minoxidil spray and aims for a shadow on his scalp rather than a full head of hair.

A 23-year-old experienced significant hair regrowth in 3 months using a topical mixture of minoxidil 5% and finasteride 1%, with added bimatoprost. The treatment is government-subsidized, costing around $15, and the user reported no side effects.

Topical finasteride may have higher systemic absorption and lower efficacy when using a Propylene Glycol/Ethanol formulation compared to the hydroxypropyl chitosan (HPCH) formulation. The safety profile of topical finasteride relies heavily on the HPCH formulation, and using standard solutions might lead to different pharmacokinetics.

Breezula's phase 3 results are expected in July or August, with commercialization possibly in two years. There are concerns about delays and effectiveness, and the cost may be high.

The conversation is about a potential new hair loss treatment called Breezula CB-03-01. Users are discussing updates on its development and sharing personal experiences with making or using it.

The conversation discusses a hair loss and scalp care routine involving ciclopirox shampoo, benzoyl peroxide, clindamycin gel, clobetasol propionate, and calcipotriol to manage seborrheic dermatitis, folliculitis, and inflammation. It also touches on the role of diet and other treatments like oral minoxidil and pioglitazone for scalp health.

A user is seeking a pharmacy to compound a topical solution containing Minoxidil, Finasteride, Alfatradiol, Melatonin, Latanoprost, and either RU58841 or Pyrilutamide. They prefer a professional compounding lab over DIY methods.

The user reported hair thickening and new growth after using minoxidil and microneedling for over three months. They are considering finasteride but have not started it yet.

User seeks availability of Breezula and its delayed trials. Asks for success with similar topical antiandrogens like fluridil.

The conversation is about the use of peptide therapies for hair loss, specifically GHK-CU, ZN-Thymulin, and PTD-DBM. The user is seeking feedback on the effectiveness of these treatments from those who have tried them.

Scientists at UCLA have developed a promising treatment for male pattern baldness using a molecule called PP405, which can potentially stimulate dormant hair follicles. Initial trials showed significant results within a week, but larger clinical trials are needed to confirm its efficacy and safety.

Amplifica starting clinical trials for new hair loss drug. SCUBE3 protein discovered, stimulates hair growth, could be alternative to Minoxidil and Finasteride.

The user experienced significant hair regrowth in three months using 1mg finasteride three days a week and topical minoxidil daily, with initial side effects from finasteride that resolved after adjusting the dosage. They used liquid minoxidil from the Kirkland brand and initially included microneedling in their routine.

PTD-DBM is being explored for hair regrowth by targeting CXXC5, with clinical trials expected after pre-clinical studies. Users express anticipation and skepticism about its effectiveness.

Zinc pyrithione and piroctone olamine are effective for reducing hair shedding, possibly more so than ketoconazole. There is a concern about zinc pyrithione shampoo interfering with minoxidil, but it's unclear if this is proven.

Hope Medicine's HMI-115 is expected to be released in 2027, with phase 3 trials currently recruiting. Concerns include the safety of targeting prolactin and the potential cost of the treatment.

Verteporfin is being explored for hair regeneration, with unofficial trials and updates shared online. Efforts are being made to encourage more surgeons to trial verteporfin for donor hair regeneration.

Switching from liquid to foam Minoxidil to avoid scalp irritation, with a method to melt the foam for easier application. Users discuss alternatives and personal experiences with Minoxidil, including issues with propylene glycol and different application methods.

The conversation is about a person's 3.5-month hair regrowth progress using a combination of 8% topical minoxidil with 0.1% finasteride and 0.01% tretinoin, 5 mg oral minoxidil, and weekly use of a 1.5mm dermapen.

PP405 may promote short-term hair growth by pushing follicles into the growth phase, but concerns exist about long-term effects due to lack of rest phases. Users discuss various treatments like finasteride, minoxidil, spironolactone, alfatradiol, and investigational drugs like KX-826 and GT20029 for hair maintenance and regrowth.

Using 0.1% Alfatradiol and 1% Pyrilutamide stopped hair loss, reducing shedding from over 150 hairs a day to less than 10, with no side effects. The user also uses Minoxidil and microneedling, applying the treatments twice daily.

The conversation discusses the effectiveness of adding RCP (redensyl, capixyl, procapil) to a hair loss treatment regimen that includes minoxidil and finasteride. Users share experiences, suggesting RCP may not be as effective as minoxidil, but could be useful for creating topical solutions.

A user received a prescription for a topical solution with Minoxidil 7%, Finasteride 2%, and Tretinoin 0.01%, to be used twice daily for three months. They are concerned about the safety of these dosages compared to commonly recommended lower dosages.

A 23-year-old male shared his 4-month progress using a topical spray with 0.3% Finasteride, 7% Minoxidil, 2.2% Ketoconazole, and 0.2% Biotin, along with microneedling. He noticed new hair growth on his temples and experienced initial shedding, with no significant side effects after the first month.

The conversation discusses biannual SCUBE3 injections and microneedling as treatments for hair loss. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

Recruitment for a verteporfin trial and a separate hair cloning trial using verteporfin and other methods is underway, with locations in Jordan, NYC, Beverly Hills, and Memphis. Dr. Bloxham is conducting the hair cloning trial, and interested participants are encouraged to contact him directly.

PP405 is viewed skeptically, with some seeing it as overhyped and potentially ineffective compared to existing treatments like minoxidil and finasteride. While it shows some promise in activating dormant hair follicles, many believe it won't replace hair transplants or significantly outperform current options.

Amplifica's progress on Scube3 is unclear, with no recent updates. The conversation also mentions Minoxidil, finasteride, and RU58841 as hair loss treatments.